A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Daniel MojHugo MaasAndré SchaeftleinNina HankeJosé David Gómez-MantillaThorsten Lehr

Published in: Clinical pharmacokinetics (2020)

This is the first implementation of a PBPK model for dabigatran to distinguish between the prodrug, active moiety, and main active metabolite. Following adjustment of the UGT2B15 metabolism and P-gp transport rates, the PBPK model accurately predicts the pharmacokinetics in renally impaired patients.

Keyphrases

end stage renal disease
atrial fibrillation
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
healthcare
primary care
patient reported
drug release